logo
  • Resources by Tumor Type
  • Provider Resources
    • Care Step Pathways
    • Continuing Education
    • Provider Toolkits
    • Healthcare Disparities
      • Primer
      • Videos
    • ctDNA Testing for Response Monitoring
    • News
  • Patient/Caregiver Resources
    • Patient Action Plans
    • Caregiver Resource
    • Options for Stage IV Melanoma
    • Options for Stage III Melanoma
    • Options for Stage II Melanoma
    • Non-Invasive Evaluation Tools (Melanoma)
    • ctDNA Testing Handout
  • International Resources
    • Australia
    • Canada
    • France
    • Germany
    • Italy
    • Portugal
    • Spain
    • UK
  • Videos
    • HCP Videos
    • Patient Videos
  • Resources by Tumor Type
  • Provider Resources
    • Care Step Pathways
    • Continuing Education
    • Provider Toolkits
    • Healthcare Disparities
      • Primer
      • Videos
    • ctDNA Testing for Response Monitoring
    • News
  • Patient/Caregiver Resources
    • Patient Action Plans
    • Caregiver Resource
    • Options for Stage IV Melanoma
    • Options for Stage III Melanoma
    • Options for Stage II Melanoma
    • Non-Invasive Evaluation Tools (Melanoma)
    • ctDNA Testing Handout
  • International Resources
    • Australia
    • Canada
    • France
    • Germany
    • Italy
    • Portugal
    • Spain
    • UK
  • Videos
    • HCP Videos
    • Patient Videos
Avatar photo
  • Profile
  • Topics Started
  • Replies Created
  • Engagements
  • Favorites

Forum Topics Started

Viewing 10 topics - 1 through 10 (of 10 total)
    • Topic
    • Voices
    • Posts
    • Last Post
    • New BRAF/MEK inhibitors coming to market

      Started by: Avatar photoLisa Kottschade in: Dosing and administration

    • 1
    • 1
    • March 1, 2018 at 12:20 am

      Lisa Kottschade

    • Adjuvant Immunotherapy in stage IIIA patients

      Started by: Avatar photoLisa Kottschade in: Expectations for therapy

    • 1
    • 1
    • March 1, 2018 at 12:16 am

      Lisa Kottschade

    • Influenza and Tamiflu and Immunotherapy

      Started by: Avatar photoLisa Kottschade in: Other

    • 3
    • 3
    • February 25, 2018 at 10:12 pm

      Kathleen Madden

    • Infusion times

      Started by: Avatar photoLisa Kottschade in: Dosing and administration

    • 8
    • 11
    • February 15, 2018 at 3:41 pm

      Lisa Kottschade

    • Probiotics

      Started by: Avatar photoLisa Kottschade in: Side-effect management

    • 5
    • 7
    • February 7, 2018 at 3:43 pm

      Krista Rubin

    • Sugar and melanoma

      Started by: Avatar photoLisa Kottschade in: Nutrition

    • 3
    • 4
    • January 31, 2018 at 8:43 pm

      Lisa Kottschade

    • Adjuvant Ipi vs. Nivo

      Started by: Avatar photoLisa Kottschade in: Other

    • 4
    • 7
    • January 31, 2018 at 8:37 pm

      Lisa Kottschade

    • Pre-existing rheumatologic conditions

      Started by: Avatar photoLisa Kottschade in: Side-effect management

    • 3
    • 3
    • January 5, 2018 at 2:50 am

      Virginia Seery

    • BRAF/MEK inhibitors and statins

      Started by: Avatar photoLisa Kottschade in: Side-effect management

    • 3
    • 6
    • December 14, 2017 at 4:47 pm

      Virginia Seery

    • Herbal medications

      Started by: Avatar photoLisa Kottschade in: Alternative/complementary therapies

    • 2
    • 2
    • November 30, 2017 at 8:08 pm

      Virginia Seery

  •  

Viewing 10 topics - 1 through 10 (of 10 total)

Login

Log In
Register Lost Password

Latest Activity

  • New BRAF/MEK inhibitors coming to market
    topic by Lisa Kottschade
    March 1
    in Dosing and administration
  • Adjuvant Immunotherapy in stage IIIA patients
    topic by Lisa Kottschade
    March 1
    in Expectations for therapy
  • Influenza and Tamiflu and Immunotherapy
    reply by Kathleen Madden
    February 25
    in Other
  • ASCO/NCCN guidlines now out
    reply by Mollie Reed
    February 23
    in Side-effect management
  • hepatotoxicity
    reply by Mollie Reed
    February 23
    in Side-effect management
© 2023 ImmunoHub.org. All rights reserved.
  • About
  • Terms
  • Privacy
  • Contact